CARDAMYST Coverage Doubles to Over 50%, Signaling a Pivotal Launch Inflection

What happened

Milestone Pharmaceuticals’ second-quarter 2026 update reveals that CARDAMYST now has commercial coverage for over 50% of U.S. insured lives, a dramatic improvement from the ~25% level disclosed just months ago. This leap significantly de-risks the access bottleneck that anchored prior bear scenarios, fulfilling a key condition for a more bullish thesis. However, the milestone shifts the focus to whether expanded coverage is translating into repeat patient use and material net revenue, as earlier scripts-per-patient hovered near 1.0x. The company’s ability to convert this access into durable, paid demand will determine if the launch can achieve the $40M–$60M annualized sales envisioned in the bull case. With the runway extending into the second half of 2027, the improved coverage map offers a stronger foundation, but the next quarterly KPIs on refill rates and gross-to-net trends remain the critical proof points.

Implication

Milestone’s leap to majority commercial coverage is a clear trigger for thesis reassessment, directly aligning with the DeepValue report’s condition for increasing conviction. Yet, the real test now lies in whether this broad access yields higher scripts per patient and reduces gross-to-net volatility, as prior launch data showed only early breadth without persistence. The company’s cash runway provides breathing room, but the 19.6% effective royalty financing cost means any sales ramp must be robust to offset high capital costs. If the next quarterly update demonstrates refill lift and revenue above $2M, the stock could re-rate toward the $2.40 bull scenario; conversely, if scripts stall despite coverage, the bear risk of sub-$10M annual sales and further dilution resurfaces. Overall, the risk-reward has improved materially, shifting the recommendation from WAIT to a more positive outlook contingent on utilization trends.

Thesis delta

The investment thesis shifts from a cautious WAIT stance as covered lives have exceeded the critical 50% threshold, addressing the primary access concern. The risk-reward now tilts more favorably, but full conviction still depends on observing that this coverage is high-quality and leads to a material rise in scripts per patient and net product revenue. The next few quarters will either confirm a durable launch trajectory or expose lingering execution hurdles beneath the coverage win.